Cargando…
Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain
Sigma receptors modulate nociception, offering a potential therapeutic target to treat pain, but relatively little is known regarding the role of sigma-2 receptors (S2R) in nociception. The purpose of this study was to investigate the in vivo analgesic and anti-allodynic activity and liabilities of...
Autores principales: | Wilson, Lisa L., Alleyne, Amy R., Eans, Shainnel O., Cirino, Thomas J., Stacy, Heather M., Mottinelli, Marco, Intagliata, Sebastiano, McCurdy, Christopher R., McLaughlin, Jay P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9182558/ https://www.ncbi.nlm.nih.gov/pubmed/35684553 http://dx.doi.org/10.3390/molecules27113617 |
Ejemplares similares
-
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
por: Cirino, Thomas J., et al.
Publicado: (2019) -
Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use
por: Wilson, Lisa L., et al.
Publicado: (2022) -
Nonpeptide Small Molecule
Agonist and Antagonist Original
Leads for Neuropeptide
FF1 and FF2 Receptors
por: Journigan, V. Blair, et al.
Publicado: (2014) -
Solid-Phase Synthesis of the Bicyclic Peptide OL-CTOP Containing Two Disulfide Bridges, and an Assessment of Its In Vivo μ-Opioid Receptor Antagonism after Nasal Administration
por: Rayala, Ramanjaneyulu, et al.
Publicado: (2023) -
Bis-Cyclic Guanidine Heterocyclic Peptidomimetics as Opioid Ligands with Mixed μ-, κ- and δ-Opioid Receptor Interactions: A Potential Approach to Novel Analgesics
por: McLaughlin, Jay P., et al.
Publicado: (2022)